ClinicalTrials.gg
CompletedNCT00721825TIERSUpdated Jul 24, 2008

Study of NeuroAid In Enhancing Recovery After Stroke

A Phase 2 interventional study of Neuroaid and Neuroaid matched Placebo in Stroke and Cerebral Infarction, sponsored by Moleac Pte Ltd.. Completed at 1 site in Singapore. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2008-07-24.

Primary conditionCerebral InfarctionRegistry: StrokeReclassifiedWhy we changed it
Registry
Stroke — the first condition term the registry derived for this study.
ClinicalTrials.gg
Cerebral Infarction
Why
  1. The study's listed conditions name Cerebral Infarction, a narrower term within Stroke.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Moleac Pte Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
21 Years to 80 Years
Sex
All
01

Study summary

TIERS is a phase II to generate detailed preliminary data on the efficacy of NeuroAid in post-stroke recovery, and to assess the utility of the rehabilitation outcome measure instruments used.

02

Conditions studied

  • Stroke
  • Cerebral Infarction

Browse trials for

Keywords

  • Stroke
  • Cerebral infarct
  • Rehabilitation
  • Double blind Randomized
  • Placebo controlled
  • Traditional Chinese Medicine
  • Neuroaid
03

In context

Cerebral Infarction Reclassified

219 studies on the registry are indexed under Cerebral Infarction; 46 are open to participants now.

This study's enrollment of 40 is below the median of 120 across 139 interventional studies indexed under Cerebral Infarction.

Browse Cerebral Infarction studies →

Lead sponsor

Moleac Pte Ltd. is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Compared within Cerebral Infarction, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject had cerebral infarction confirmed by Computed Tomography (CT scan or Magnetic Resonance Imaging (MRI) imaging
  • Presents within 1 month after stroke onset
  • Presents with motor power of from grade 1 - 4/5 in at least one limb
  • Has a pre-stroke modified Rankin score ≤ 1.
  • Age between 21 and 80 years old
  • Female subjects are eligible to participate in the trial if they are of non (hysterectomy or )
  • Subject or legally acceptable representative is willing and able to provide written
  • Subject and carer are willing and able to comply with drug administration schedule.

Exclusion criteria

Exclusion Criteria:

  • Subject has received thrombolysis
  • Subject has evidence of intra-cerebral hemorrhage on brain CT scan or MRI
  • Subject has definite indication for full-dose or long-term anticoagulation therapy
  • Subject has other significant non-ischemic brain lesion which could affect function disability
  • Subject has co-existing systemic diseases: terminal cancer, renal failure (creatinine >200 μmol/L, if known), cirrhosis, severe dementia or psychosis
  • Subject has a history of previous stroke/s
  • Subject has participated in another clinical trial within the last three months
  • Subject has aphasia or any other cognitive disabilities which prevent cooperation with study instructions
  • Subject has dense hemiplegia (grade 0 motor power)
  • Subject has level of \<10mg/dl on admission
  • Subject has a history of craniotomy or seizures
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    1

    Neuroaid

    Drug: Neuroaid

  • Placebo comparator
    2

    Neuroaid matched placebo

    Drug: Neuroaid matched Placebo

Interventions

  • Neuroaid capsules, 4 capsules, three times per day, during one month

  • DrugNeuroaid matched Placebo

    Neuroaid matched placebo 4 capsules three times per day during one month

06

What researchers measure

Primary outcomes

  1. Fugl-Meyer assessment

    Time frame: 4 weeks

Secondary outcomes

  1. Functional Independence Measure (FIM) scale

    Time frame: 4 weeks and 8 weeks

  2. Fugl-Meyer subscores

    Time frame: 4 weeks and 8 weeks

  3. NIHSS and NIHSS subscores

    Time frame: 4 weeks and 8 weeks

07

Study locations

1 site
  • Tan Tock Seng Rehabilitation department
    Singapore, 569766, Singapore
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2008
First posted
Jul 24, 2008
Start
Jan 2008
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Last update
Jul 24, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00721825
Lead sponsor
Moleac Pte Ltd.
First posted
Jul 24, 2008
Start date
Jan 2008
Primary completion
Jul 2008
Completion
Jul 2008
Last update
Jul 24, 2008

Study contacts

Keng He Kong, MD
principal investigator · Tan Tock Seng Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Neuroaid

Start the discussion